Altimmune, Inc. (ALT)
NASDAQ · Manufacturing · Pharmaceutical preparations
$3.06+$0.0200 (+0.66%) on the dayAs of the close; data may be delayed.
ALT price, last 12 months
Key stats
- Previous close
- $3.04
- Open
- $3.05
- Day range
- $3.00 – $3.11
- 52-week range
- $2.56 – $6.44
- Volume
- 2.9M
- Avg volume (20 days)
- 3.8M
- Market cap
- $595.2M
Performance
1W−5.9%
1M−2.9%
3M+8.5%
6M−4.4%
YTD−15.2%
1Y−21.9%
vs S&P 500, 1Y−38.7 pts
Technicals and fundamentals
About Altimmune, Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $595.2M